Solmi, Marco http://orcid.org/0000-0003-4877-7233
Cortese, Samuele
Vita, Giovanni
De Prisco, Michele http://orcid.org/0000-0002-2032-1181
Radua, Joaquim
Dragioti, Elena http://orcid.org/0000-0001-9019-4125
Köhler-Forsberg, Ole
Madsen, Nanna M.
Rohde, Christopher
Eudave, Luis
Aymerich, Claudia
Pedruzo, Borja
Rodriguez, Victoria
Rosson, Stella http://orcid.org/0000-0002-8554-3519
Sabé, Michel http://orcid.org/0000-0002-8530-5596
Hojlund, Mikkel http://orcid.org/0000-0002-5786-5203
Catalan, Ana
de Luca, Beatrice
Fornaro, Michele http://orcid.org/0000-0002-9647-0853
Ostuzzi, Giovanni
Barbui, Corrado http://orcid.org/0000-0003-1073-9282
Salazar-de-Pablo, Gonzalo
Fusar-Poli, Paolo http://orcid.org/0000-0003-3582-6788
Correll, Christoph U.
Article History
Received: 22 June 2023
Revised: 21 September 2023
Accepted: 6 October 2023
First Online: 13 November 2023
Competing interests
: CUC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantic. CR received the 2020 Lundbeck Foundation Talent Prize. OK-F received honoraria for lectures for Lundbeck Pharma A/S and consultant work for WCG Clinical. MH has been consultant for or has received honoraria from: H. Lundbeck, The Lundbeck Foundation and Otsuka. MS received honoraria/has been a consultant for AbbVie, Angelini, Lundbeck, Otsuka. All other authors declare no conflict of interest.
: Ethical approval for this study was not required.
: Authors declare manuscript is an honest, accurate, and transparent account of the study being reported; no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained in published protocol.